Antibodies are the most rapidly growing drug class and have a major impact on human
health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of …

The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Monoclonal antibodies (mAbs) are well established in the clinic due to their specificity and
affinity to a diverse array of biochemical targets. More recently, mAbs are being exploited as …

It has been over four decades since the development of monoclonal antibodies (mAbs)
using a hybridoma cell line was first reported. Since then more than thirty therapeutic …

Antibody drugs have become an increasingly significant component of the therapeutic
landscape. Their success has been driven by some of their unique properties, in particular …

The ability of monoclonal antibodies to specifically bind a target antigen and neutralize or
stimulate its activity is the basis for the rapid growth and development of the therapeutic …

The field of targeted therapeutics has benefitted immeasurably from the development of high-
affinity antibodies. These important ligands have facilitated the development of effective …

Monoclonal antibodies have evolved from research tools to powerful therapeutics in the past
30 years. Clinical success rates of antibodies have exceeded expectations, resulting in …

Antibody-based therapies have garnered considerable success in recent years. This is due
to the availability of strategies to successfully engineer antibodies into humanized forms …

Targeted therapeutics such as monoclonal antibodies (mAbs) have proven successful as
cancer drugs. To profile products that could be marketed in the future, we examined the …